Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab ± Tremelimumab Consolidation After cCRT in Limited-Stage SCLC
jRCT2080224104Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Durvalumab consolidation, Durvalumab + tremelimumab consolidation and Placebo consolidation (3 arms). Started Oct 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2080224104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224104.